Last reviewed · How we verify
Tegoprazan 50 mg, tablets, orally, qd
Tegoprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion.
Tegoprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the H+/K+-ATPase pump in gastric parietal cells to reduce gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Acid-related gastrointestinal disorders.
At a glance
| Generic name | Tegoprazan 50 mg, tablets, orally, qd |
|---|---|
| Sponsor | Zhang Xiaofeng,MD |
| Drug class | Potassium-competitive acid blocker (P-CAB) |
| Target | H+/K+-ATPase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Unlike proton pump inhibitors (PPIs) that irreversibly block the H+/K+-ATPase, tegoprazan competitively inhibits this pump in a potassium-dependent manner, allowing for more rapid onset and offset of acid suppression. This mechanism may provide faster symptom relief and potentially fewer drug-drug interactions compared to traditional PPIs. Tegoprazan is used to treat acid-related gastrointestinal disorders by maintaining elevated gastric pH.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Acid-related gastrointestinal disorders
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
Key clinical trials
- Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1) (PHASE4)
- Pharmacokinetic Interaction Between Tegoprazan and NSAIDs After Multiple Oral Dosing in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tegoprazan 50 mg, tablets, orally, qd CI brief — competitive landscape report
- Tegoprazan 50 mg, tablets, orally, qd updates RSS · CI watch RSS
- Zhang Xiaofeng,MD portfolio CI